Moffitt Cancer Center Executive Leadership

patrick-hwu-profile

Patrick Hwu, MD

President and CEO

Patrick Hwu, MD, is the president and CEO of Moffitt Cancer Center, one of the nation’s leading cancer hospitals and the only National Cancer Institute-designated comprehensive cancer center based in Florida.

Patrick Hwu top moments of 2021
Moffitt CEO Dr. Patrick Hwu reflects on the successes from his first year. Read more

As an internationally recognized tumor immunologist, Dr. Hwu has led pioneering research and clinical efforts to better understand the interactions between tumors and the immune system. He helped launch the field of gene-modified T cells, publishing research on the first chimeric antigen receptor directed against cancer. His work focuses on vaccines, adoptive T-cell therapies and immune resistance. An internationally recognized physician-scientist, Hwu has a proven track record leading collaborative teams to make breakthroughs in science while improving cancer outcomes for cancer patients.

Prior to joining Moffitt, Dr. Hwu was the head of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, where he held various leadership roles for 17 years. In 2003, he was recruited as the first chairman of the Department of Melanoma Medical Oncology. He was also the associate director of the Center for Cancer Immunology Research (2004) and chair of the Department of Sarcoma Medical Oncology (2012).

Dr. Hwu earned his medical degree from The Medical College of Pennsylvania. He served as a house officer in Internal Medicine at The Johns Hopkins Hospital and completed a fellowship in oncology at the National Cancer Institute, where he worked as a principal investigator leading tumor immunology studies.

Request an Appointment See our Patient Outcomes


Follow Dr. Hwu



Related Stories

Moffitt CEO Focuses Research on Creating ‘Super Soldiers’
Hwu’s lab seeks out new T-cell therapies for some of the toughest cancers

Moffitt Leads 1st COVID Vaccine Study in Cancer Patients
600 enrolled to determine effectiveness in those undergoing treatment

Speeding Up Cellular Immunotherapy
New ‘off the shelf’ CAR T product shows promise in phase 1 study